Recommended procedures for the treatment and diagnostics of hepatocellular carcinoma
Authors:
R. Brůha 1; J. Šperl 1
; P. Urbánek 1; J. Špičák 2; I. Kiss 3; V. Válek4 ,6; V. Mejzlík 5; M. Oliverius 5; E. Honsová 7; P. Husa Za Pracovní Skupinu Hcc 8 2011
Authors place of work:
Česká hepatologická společnost ČLS JEP
1; Česká gastroenterologická společnost ČLS JEP
2; Česká onkologická společnost ČLS JEP
3; Česká společnost intervenční radiologie ČLS JEP
4; Česká transplantační společnost
5; Radiologická společnost ČLS JEP
6; Společnost českých patologů ČLS JEP
7; Společnost infekčního lékařství ČLS JEP
8
Published in the journal:
Gastroent Hepatol 2012; 66(2): 83-92
Category:
Hepatology: Best Practises
Zdroje
1. International Agency for Cancer Reseach. GLOBOCAN 2002: http://www-dep.iarc.fr Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127 (5 Suppl 1): S5–S16.
2. AASLD guidelines for HCC. http://www.aasld.org/practiceguidelines/Documents//Bookmarked%20Practice%20Guidelines//HCCUpdate2010.pdf.
3. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130(7): 417–422.
4. Yuen MF, Tanaka Y, Fong DY et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009; 50(1): 80–88.
5. Lok AS, Seeff LB, Morgan TR et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136(1): 138–148.
6. Guyatt GH, Oxman AD, Vist GE et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336(7650): 924–926.
7. Singal A, Volk ML, Waljee A et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30(1): 37–47.
8. Lok AS, Sterling RK, Everhart JE et al. HALT-C Trial Group. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010; 138(2): 493–502.
9. Bruix J, Sherman M. Management of Hepatocellular Carcinoma: An Update. Hepatology 2011; 53(3): 1020–1022.
10. International Consensus group for hepatocellular neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009; 49(2): 658–664.
11. Forner A, Vilana R, Ayuso C et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008; 47(1): 97–104.
12. Sangiovanni A, Manini MA, Iavarone M et al. The diagnostic and economic impact of contrast paging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010; 59(5): 638–644.
13. Edge SB, Byrd DR, Compton CC et al. AJCC Cancer Staging Manual 7th edition. Springer, 2010.
14. Pugh RNH, Murray-Lyon IM, Dawson JL et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60(8): 646–664.
15. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33(2): 464–470.
16. Forner A, Reig ME, de Lope CR et al. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30(1): 61–74.
17. Llovet, JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005; 25(2): 181–200.
18. Schwartz M. Liver transplantation for hepatocellular carcinoma. Gastroenterology 2004; 127 (Suppl 1): S268–276.
19. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334(11): 693–699.
20. Livraghi T, Meloni F, Di Stasi M et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 2008; 47(1): 82–89.
21. Lin SM, Lin CJ, Lin CC et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm. Gastroenterology 2004; 127: 1714–1723.
22. Cho YK, Kim JK, Kim MY et al. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009; 49(2): 453–459.
23. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004; 127 (5 Suppl 1): S179–188.
24. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37(2): 429–442.
25. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359(4): 378–390.
26. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol 2009; 10(1): 25–34.
Štítky
Paediatric gastroenterology Gastroenterology and hepatology SurgeryČlánok vyšiel v časopise
Gastroenterology and Hepatology
2012 Číslo 2
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole vs. Tramadol in Postoperative Analgesia
- Spasmolytic Effect of Metamizole
- Possibilities of Using Metamizole in the Treatment of Acute Primary Headaches
- Current Insights into the Antispasmodic and Analgesic Effects of Metamizole on the Gastrointestinal Tract
Najčítanejšie v tomto čísle
- Hepatorenal syndrome in patients with acute alcoholic hepatitis
- Current approach to anaemia in patients with inflammatory bowel disease
- Treatment of achalasia – the current approach and personal experience
- Prof. Jiří Nevoral on the occasion of his 70th birthday